# Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib

> **NCT02056080** · — · COMPLETED · sponsor: **MedSIR** · enrollment: 111 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02056080
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02056080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02056080, "Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02056080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*